XML 33 R23.htm IDEA: XBRL DOCUMENT v3.23.3
Net Loss Per Share (Tables)
9 Months Ended
Sep. 30, 2023
Earnings Per Share [Abstract]  
Schedule of Earnings Per Share, Basic and Diluted

Basic and diluted net loss per share attributable to common stockholders was calculated as follows:

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

(in thousands, except per share data)

 

 

(in thousands, except per share data)

 

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

Numerator:

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

$

(22,263

)

 

$

(29,050

)

 

$

(70,981

)

 

$

(79,116

)

Denominator:

 

 

 

 

 

 

 

 

 

 

 

 

Weighted-average number of common shares outstanding – basic and diluted

 

 

97,033,273

 

 

 

87,892,195

 

 

 

91,268,133

 

 

 

87,868,081

 

Net loss per share – basic and diluted

 

$

(0.23

)

 

$

(0.33

)

 

$

(0.78

)

 

$

(0.90

)

In August 2023, the Company completed a private placement, in which 13,196,671 shares of common stock were sold together with pre-funded warrants to purchase 2,340,579 shares of common stock with an exercise price of $0.0001 per share. The pre-funded warrants were classified as a component of permanent equity in the Company's condensed consolidated balance sheet as they are freestanding financial instruments that are immediately exercisable, do not embody an obligation for the Company to repurchase its own shares and permit the holders to receive a fixed number of shares of common stock upon exercise. All of the shares underlying

the pre-funded warrants have been included in the weighted-average number of shares of common stock used to calculate net loss per share attributable to common stockholders because the shares may be issued for little or no consideration, are fully vested and are exercisable after the original issuance date of the pre-funded warrants.

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:

 

 

September 30,

 

 

 

2023

 

 

2022

 

Stock options to purchase common stock

 

 

17,095,005

 

 

 

12,701,089

 

Unvested restricted common stock

 

 

757,647

 

 

 

 

Total

 

 

17,852,652

 

 

 

12,701,089